Phase III trials for Chinese company Cansinobio's COVID-19 vaccine launched: NCOC

States schools to open on previously decided schedule


Razya Khan September 22, 2020

The National Command and Operation Centre (NCOC) on Tuesday announced that phase III clinical trials for the Covid-19 vaccine will be launched in Pakistan.

The trial is a partnership between the National Institute of Health (NIH) and the CanSinoBio and Beijing Institute of Biotechnology China [BIB].

The trials have begun, said Dr Hasan, an official with the pharmaceutical company.

"Just launched the Phase III trials for a COVID-19 vaccine in Pakistan," said Federal Minister for Planning and Development, Asad Umar.

The minister stated phase III clinical trials for a Covid-19 vaccine in Pakistan has been launched and a total of 40,000 people will participate in this trial from seven different countries.

In a tweet, the federal minister said that from 40,000 participants, 8,000 to 10,000 will be Pakistani, adding that initial results are expected in four to six months.

Earlier in September, China National Biotec Group (CNBG) and Sinovac Biotech Ltd said four more countries have agreed to run late-stage clinical tests of their coronavirus vaccine candidates, as China steps up its efforts in the global race.

Serbia and Pakistan were among the new countries agreeing to Phase 3 trials, as the two companies seek more data overseas amid dwindling new cases in China.

The meeting also maintained that educational institutions will reopen as previously decided. The second phase - classes 6 to 8 - will reopen from tomorrow.

 

 

 

 

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ